IL297316A - Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors - Google Patents

Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Info

Publication number
IL297316A
IL297316A IL297316A IL29731622A IL297316A IL 297316 A IL297316 A IL 297316A IL 297316 A IL297316 A IL 297316A IL 29731622 A IL29731622 A IL 29731622A IL 297316 A IL297316 A IL 297316A
Authority
IL
Israel
Prior art keywords
carbonyl
pyrimidin
amino
pyrazolo
methyl
Prior art date
Application number
IL297316A
Other languages
English (en)
Hebrew (he)
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of IL297316A publication Critical patent/IL297316A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL297316A 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors IL297316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
IL297316A true IL297316A (en) 2022-12-01

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297316A IL297316A (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Country Status (12)

Country Link
US (1) US20230158031A1 (enExample)
EP (1) EP4138836A1 (enExample)
JP (2) JP2023522693A (enExample)
KR (1) KR20230015346A (enExample)
CN (1) CN115443136A (enExample)
AU (1) AU2021261327A1 (enExample)
BR (1) BR112022020974A2 (enExample)
CA (1) CA3175788A1 (enExample)
IL (1) IL297316A (enExample)
MX (1) MX2022013164A (enExample)
TW (1) TW202206076A (enExample)
WO (1) WO2021216696A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
EP2773639B1 (en) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Also Published As

Publication number Publication date
BR112022020974A2 (pt) 2022-12-06
AU2021261327A1 (en) 2022-12-22
WO2021216696A1 (en) 2021-10-28
CN115443136A (zh) 2022-12-06
TW202206076A (zh) 2022-02-16
JP2026027386A (ja) 2026-02-18
KR20230015346A (ko) 2023-01-31
JP2023522693A (ja) 2023-05-31
CA3175788A1 (en) 2021-10-28
MX2022013164A (es) 2022-11-30
US20230158031A1 (en) 2023-05-25
EP4138836A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
US20230338370A1 (en) Treatment of Cancer with TOR Kinase Inhibitors
EP2825170B1 (en) Treatment of cancer with tor kinase inhibitors
AU2014205472B2 (en) Deuterated momelotinib
US11013741B1 (en) AXL kinase inhibitors and use of the same
AU2015364335A1 (en) Treatment of pemphigus
AU2017275650B2 (en) Pharmaceutical combinations
US20140213553A1 (en) Carbamoylpyridone derivatives
JP7701758B2 (ja) 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2026027386A (ja) Ｂｔｋ阻害剤を使用するサイトカインストームを包含する急性呼吸窮迫症候群および他の障害の処置
JP2023509168A (ja) ＢＴＫ阻害剤２－［（３Ｒ）－３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを使用する、膜性腎症、ＩＧＧ４関連疾患、及び抗リン脂質症候群の処置
JP2024546846A (ja) マントル細胞リンパ腫の治療のためのアベマシクリブ並びにＰＩ３Ｋ阻害剤及び／又はｍＴＯＲ阻害剤を含む薬剤の組み合わせ
JP7289978B1 (ja) がん治療のための併用療法
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
HK40101405A (zh) C21H22Cl2N4O2的晶型
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors